The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 27, 2008
Filed:
Apr. 12, 2001
Olaf Peters, Jena, DE;
Alexander Hillisch, Jena, DE;
Ina Thieme, Graitschen, DE;
Walter Elger, Berlin, DE;
Christa Hegele-hartung, Muelheim a. d Ruhr, DE;
Uwe Kollenkirchen, Berlin, DE;
Karl-heinrich Fritzemeier, Berlin, DE;
Vladimir Patchev, Jena, DE;
Olaf Peters, Jena, DE;
Alexander Hillisch, Jena, DE;
Ina Thieme, Graitschen, DE;
Walter Elger, Berlin, DE;
Christa Hegele-Hartung, Muelheim a. d Ruhr, DE;
Uwe Kollenkirchen, Berlin, DE;
Karl-Heinrich Fritzemeier, Berlin, DE;
Vladimir Patchev, Jena, DE;
Schering Aktiengesellschaft, Berlin, DE;
Abstract
This invention describes the new 8β-substituted estratrienes of general formula I in which R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, Rand Rhave the meanings that are indicated in the description, and Rmeans a straight-chain or branched-chain, optionally partially or completely halogenated alkyl or alkenyl radical with up to 5 carbon atoms, an ethinyl- or prop-1-inyl radical, as pharmaceutical active ingredients that have in vitro a higher affinity to estrogen receptor preparations of rat prostates than to estrogen receptor preparations of rat uteri and in vivo preferably a preferential action on bone rather than the uterus and/or a pronounced action with respect to stimulation of the expression of 5HT2a-receptors and 5HT2a-transporters, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The invention also describes the use of these compounds for treatment of estrogen-deficiency-induced diseases and conditions as well as the use of an 8β-substituted estratriene structural part in the total structures of compounds that have a dissociation in favor of their estrogenic action on bones rather than the uterus.